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R&D intensity is critical to the growth of hi-tech sectors like pharmaceuticals and information technology and is aimed at 
boosting innovation. In turn, innovation brings new products that could earn revenues to further boost R&D intensity1. 
Indian pharmaceutical industry earns nearly sixty percent of its revenues from exports and is a leader in global generics 
market with largest share of ANDA and DMF filings. Significant increase in patenting activity is also observed post India’s 
accession to TRIPS agreement in 1995 and subsequent introduction of Product Patent Regime in 20052. This study aims at 
establishing a causal relationship amongst R&D intensity, patents, regulatory filings and export intensity. Also, the impact 
of these variables on export intensity of Indian Pharmaceutical sector has been studied by fitting them into an  
econometric model. 
 
Keywords: Technology Management, R&D intensity, Export intensity, Innovation and export intensity, patents, Indian 
Pharmaceutical Industry 
 
Introduction 
The study uses real financial data for Indian 
pharmaceutical industry for period 2000-01 to 2013-
14 as shown in table 1. The study period starts from 
2000-01 as the R&D intensity of Indian 
pharmaceutical industry; patent data as well as 
regulatory filings were negligible prior to 2000-01. As 
the study takes into the regulatory filings, therefore 
the data up to 2013-14 has been taken into account as 
USFDA was reporting ANDA and DMF filings till 
2013-14 and thereafter the reporting pattern changed 
to ANDA and DMF approvals. For this reason, the 
study period was selected as 2000-01 to 2013-14.The 
data for exports and R&D expenditure have been 
drawn from Center for Monitoring of Indian Economy 
(CMIE), Prowess Database. Data for ANDA and 
DMF filings (referred as regulatory filings) have been 
taken from annual reports of Department of 
Pharmaceuticals, Government of India& United 
States Food and Drug Administration (USFDA). 
Patent data has been extracted from World Intellectual 
Property Organization (WIPO) Statistics Database
3
. 
Eviews 8 was used for statistical and econometric 
analysis. All data points were made stationary by 
converting to natural log and then taking first 
difference. This study attempts at determining a 
causal relationship between variables namely; R&D 
intensity (RDI), pharmaceutical export intensity 
(PEI), regulatory filings (RF), and total patents 
granted (TP). Econometric analysis was performed 
using Granger causality to test two way causal 
relationships amongst the variables. This was 
followed by fitting the variables into Autoregressive 
distributed lag (ARDL) model. 
 
Results and Discussion 
It was found that R&D intensity Granger causes 
export intensity. A two way causal relationship was 
found between regulatory filings and R&D intensity. 
Similarly, a two way causal relationship was observed 
amongst variables; total patents and regulatory filings. 
Also, total patents granted as well as regulatory filings 
were found to be Granger causing pharmaceutical 
export intensity as shown in table 2. The results of 
Granger causality tests can be explained with the fact 
that R&D expenditure is aimed at developing new 
products for domestic as well as overseas markets. 
Firms invest in R&D to boost their presences in 
regulated  markets  like  US  and  Europe  and that the  
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Table 2 — Results of Econometric Analysis 
Pairwise Granger Causality Tests 
Sample: 1 14  
Lags: 1   
    
 Null Hypothesis: Obs F-Statistic Prob.  
    
 DPEI does not Granger Cause DRDI  12  0.60300 0.4574 
 DRDI does not Granger Cause DPEI  3.75138 0.0847 
    
 DRF does not Granger Cause DRDI  12  20.0445 0.0015 
 DRDI does not Granger Cause DRF  78.3758 1.E-05 
    
 DTP does not Granger Cause DRDI  12  64.8069 2.E-05 
 DRDI does not Granger Cause DTP  469.740 4.E-09 
    
 DRF does not Granger Cause DPEI  12  3.89655 0.0798 
 DPEI does not Granger Cause DRF  0.93581 0.3586 
    
 DTP does not Granger Cause DPEI  12  3.90333 0.0796 
 DPEI does not Granger Cause DTP  0.81170 0.3911 
    
 DTP does not Granger Cause DRF  12  17.6064 0.0023 
 DRF does not Granger Cause DTP  12.5278 0.0063 
    
ARDL Model 
Dependent Variable: PEI   
Method: Least Squares   
Sample (adjusted): 2 14   
Included observations: 13 after adjustments  
     
Variable Coefficient Std. Error t-Statistic Prob.  
RDI 7.830368 2.846284 2.751085 0.0403 
LNTP -0.129055 0.097836 -1.319097 0.2443 
LNRF 0.249905 0.215931 1.157340 0.2994 
C -1.387805 0.445791 -3.113127 0.0265 
PEI(-1) 0.368086 0.191750 1.919616 0.1130 
RDI(-1) -1.265347 3.769674 -0.335665 0.7508 
LNTP(-1) -0.297353 0.096082 -3.094786 0.0270 
LNRF(-1) 0.356776 0.120209 2.967952 0.0312 
     
R-squared 0.936636 Mean dependent var 0.459647 
Adjusted  
R-squared 
0.847926 S.D. dependent var 0.084393 
S.E. of 
regression 
0.032910 Akaike info criterion -
3.714808 
Sum squared 
resid 
0.005415 Schwarz criterion -
3.367147 
Log 
likelihood 
32.14625 Hannan-Quinn criter. -
3.786268 
F-statistic 10.55845 Durbin-Watson stat 1.579074 
Prob 
(F-statistic) 
0.009784    
     
Source: Result of analysis using Eviews 8 
 
ANDA and DMF approvals are one of the major 
R&D productivity indicators in India
4, 5
. ARDL model 
(Table 2) suggested that the current year R&D 
intensity had a positive and significant impact on 
pharmaceutical export intensity. Also, the lagged year 
regulatory filings had a positive and significant 
impact on export intensity of Indian pharmaceutical 
industry. Results of the ARDL model suggested that 
lagged year total patents granted to Indian 
Table 1 — Data Set: Pharmaceutical Exports, R&D Expenditure, Regulatory Filings and Patents Granted in Indian Pharmaceutical 
Industry during 2000-01 to 2013-14. 
1 Regulatory Filings  
(ANDAs & DMFs) 
Total Patents Pharma Export Intensity  
(Exports/Total revenue) 
Pharma R&D Intensity  
(R&D spend/Total Revenue) 
2000-01 229 56 0.400023 0.019931 
2001-02 255 99 0.477345 0.024177 
2002-03 345 147 0.391371 0.027066 
2003-04 413 246 0.38167 0.035952 
2004-05 573 379 0.401192 0.046411 
2005-06 624 382 0.404112 0.05069 
2006-07 649 550 0.403725 0.047615 
2007-08 762 513 0.398848 0.046945 
2008-09 769 520 0.466846 0.048782 
2009-10 836 497 0.435808 0.044427 
2010-11 849 545 0.439821 0.03999 
2011-12 897 496 0.528043 0.047597 
2012-13 1005 635 0.653466 0.053569 
2013-14 938 635 0.593169 0.048624 
Source; United States-Federal Drug Administration (USFDA), CMIE, Prowess Database, Annual reports of Department of 
Pharmaceuticals-Government of India, WIPO IP Statistics Data Center 
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pharmaceutical industry had a significant but negative 
impact on export intensity. This seems to be merely a 
statistical artifact as patents filed through PCT route 
are aimed at securing innovations in overseas markets 
and shall have a positive impact on export intensity. 
This result does not corroborate with the finding of 
previous studies wherein patenting activity is 
positively affecting pharmaceutical exports 
6
. Total 
patents granted may not have a positive impact on 
exports over one year lag as patents are mainly a 
protection for an innovative product or process. It is 
then followed by further development and testing of 
the new product which may take 3-4 years time till it 
is approved by regulatory authorities for launch 
7
.  
 
Conclusion 
It was found from the current study that Indian 
pharmaceutical exports were mainly driven by 
regulatory filings (ANDAs and DMFs) and not by 
total patents granted. It was observed that R&D 
efforts as well as R&D expenditure made by Indian 
pharmaceutical industry were focused at developing 
generics (due to patent expiries) for developed 
markets especially US and Europe. It is evident that 
fewer resources were committed towards innovative 
research resulting in fewer patents. This finding was 
validated from the fact that nearly sixty percent of the 
revenue of Indian pharmaceutical firms are from 
exports and India is has the largest share in generics 
market in the US
8
.  
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